Welcome to our dedicated page for Windtree Therape SEC filings (Ticker: WINTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Windtree Therape's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Windtree Therape's regulatory disclosures and financial reporting.
Windtree Therapeutics, Inc. reports a leadership change as Eric L. Curtis resigned from his roles as President and Chief Operating Officer, effective immediately on January 5, 2026. The company states that Jed Latkin continues to serve as President and Chief Executive Officer, and he signed the report on behalf of the company.
Windtree Therapeutics issued an aggregate principal amount of $857,142.86 in senior convertible promissory notes due November 26, 2026 to an institutional investor. The company plans to advance $450,000 to CommLoan Inc. under a letter of intent to acquire all of CommLoan’s securities and to retain $150,000 for general corporate purposes.
The notes bear interest at 10% per annum, with interest payable monthly in arrears and all remaining amounts due at maturity. They are convertible at the holder’s option into common stock at 90% of the lowest sale price during the 20 consecutive trading days before conversion, subject to a 4.99% beneficial ownership cap that can be increased to 9.99% with notice.
Windtree must use 25% of gross proceeds from a prior common stock purchase agreement to prepay the notes with a 115% prepayment premium, and a qualified equity financing of at least $1 million before maturity requires full repayment at a similar premium. The company is also required to file a resale registration statement on Form S-1 for the related securities.
Windtree Therapeutics (WINT) filed a Form 12b-25 to notify a late filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, citing the need for additional time to finalize financial statements and disclosures. The company expects to file within five calendar days of the prescribed due date.
Windtree estimates a net loss of $28.1 million for the quarter, compared to $2.7 million in the prior-year period. The estimated loss reflects a $16.1 million impairment on intangible assets and a $15.0 million loss on debt issuance related to a $10.0 million commitment note recorded at its fair value of $15.0 million, partially offset by a $3.2 million deferred tax benefit tied to the impairment. These results are preliminary and subject to change upon completion of the reporting process.
Windtree Therapeutics filed a preliminary S-1 registering up to 751,872,888 shares of common stock for resale. The registration covers up to 722,242,771 ELOC Shares tied to a common stock purchase agreement with Seven Knots, LLC, including 555,555,556 Purchase Shares issuable at the company’s discretion and up to 166,687,215 Note Shares issuable upon conversion of a $10.0 million Commitment Note. It also covers up to 29,630,117 Subject Note Shares issuable upon conversion of senior convertible promissory notes due 2026.
The company states it will not receive proceeds from selling stockholders’ resales. Separately, it may receive up to $50 million from sales of Purchase Shares to Seven Knots under the ELOC pursuant to this prospectus. The ELOC includes a 4.99% beneficial ownership cap for Seven Knots; the Subject Notes include a 4.99% cap (holders may increase to 9.99% with notice). Shares outstanding were 33,634,220 as of October 17, 2025. The company’s common stock trades on the OTCID Basic Market under “WINT.”
Windtree Therapeutics entered a financing on October 9, 2025, issuing an aggregate principal amount of $1,600,000 in senior convertible promissory notes due October 9, 2026. The notes bear 10% annual interest (360-day basis), with interest payable monthly starting November 5, 2025.
The notes are junior to the Company’s June 2025 convertible promissory note. They are convertible at the Holders’ option at a price equal to 90% of the lowest sale price for the prior 20 trading days, include a 4.99% beneficial ownership cap (increasable to 9.99% with 61 days’ notice), and pay Holders $1,500 per conversion for related processing. An automatic adjustment can lower the conversion price to 80% of the lowest 20‑day price on specified calendar dates.
Mandatory prepayments include 25% of gross proceeds from the June 26, 2024 Common Stock Purchase Agreement with a 120% premium, and full repayment after a qualified equity financing of $1,000,000 or more, also tied to a 120% premium baseline. The Company must file a Form S‑1 within 20 calendar days following October 9, 2025 to register resales. Standard events of default trigger acceleration at 120% plus accrued interest. Anti‑dilution adjusts the conversion price to any lower future issue price, and Holders may roll into future financings at 80% of the new cash price.